A study to assess the efficacy and safety of nemolizumab (CD14152) in Subjects with Prurigo Nodularis
Enrolling By Invitation
18 years - 99 years
All
Phase
3
5 participants needed
1 Location
Brief description of study
The research study is being conducted using an investigational drug called nemolizumab as a possible treatment for subjects over the age of 18 diagnosed with prurigo nodularis.
Procedures include Physical exam, Medical History, blood and urine tests, Electrocardiogram, study medication administered by injection, electronic diary completion and questionnaires. Optional biopsies and photographs.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Prurigo Nodularis
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 849297
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
